Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Yang

Showing results (61-70 of 156) with videos related to

Pageof 16
Sort By:
Annals of Surgical Oncology|February 2, 2017
Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma PatientsTristen S Park, Giao Q Phan, James C Yang, et al.
Cancer|May 7, 2008
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006Jacob A Klapper, Stephanie G Downey, Franz O Smith, et al.
European Journal of Immunology|July 20, 2024
Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Malcolm J W Sim, Ken-Ichi Hanada, Zachary Stotz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 15, 2017
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell TherapyJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2011
An antigenic peptide produced by reverse splicing and double asparagine deamidationAlexandre Dalet, Paul F Robbins, Vincent Stroobant, et al.
Clinical Advances in Hematology & Oncology : H&O|October 15, 2005
Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer researchJ Carl Barrett, L Michelle Bennett, Laura Kay Fleming, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2013
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regressionYong-Chen Lu, Xin Yao, Yong F Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitisJames C Yang, Marybeth Hughes, Udai Kammula, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressionsYong-Chen Lu, Xin Yao, Jessica S Crystal, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2023
Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigensAnup Y Parikh, Robert Masi, Billel Gasmi, et al.
Pageof 16

Showing results (61-70 of 156) with videos related to

Sort By:
Pageof 16
Annals of Surgical Oncology|February 2, 2017
Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma PatientsTristen S Park, Giao Q Phan, James C Yang, et al.
Cancer|May 7, 2008
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006Jacob A Klapper, Stephanie G Downey, Franz O Smith, et al.
European Journal of Immunology|July 20, 2024
Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Malcolm J W Sim, Ken-Ichi Hanada, Zachary Stotz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 15, 2017
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell TherapyJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2011
An antigenic peptide produced by reverse splicing and double asparagine deamidationAlexandre Dalet, Paul F Robbins, Vincent Stroobant, et al.
Clinical Advances in Hematology & Oncology : H&O|October 15, 2005
Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer researchJ Carl Barrett, L Michelle Bennett, Laura Kay Fleming, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2013
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regressionYong-Chen Lu, Xin Yao, Yong F Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitisJames C Yang, Marybeth Hughes, Udai Kammula, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressionsYong-Chen Lu, Xin Yao, Jessica S Crystal, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2023
Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigensAnup Y Parikh, Robert Masi, Billel Gasmi, et al.
Pageof 16